Author: Gotera, Carolina
Title: Treatment and research lines for the patient with COVID-19. What do we have and where are we going? Cord-id: okrpa7k7 Document date: 2020_7_27
ID: okrpa7k7
Snippet: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents the most significant global public health crisis of this generation. From the beginning of the pandemic, several publications and on-line resources about different treatment lines have been done, and development effort in response to the COVID-19 pandemic to investigate potential therapies is unprecedented. Unfortunately, until now, there is not enough evidence to recommend any s
Document: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents the most significant global public health crisis of this generation. From the beginning of the pandemic, several publications and on-line resources about different treatment lines have been done, and development effort in response to the COVID-19 pandemic to investigate potential therapies is unprecedented. Unfortunately, until now, there is not enough evidence to recommend any specific anti-COVID19 treatment. Randomized clinical trials and high-quality evidence, even in the middle of a pandemic, are needed. We provide a review of the latest published literature on the therapeutic strategies and current investigational lines for SARS-CoV-2.
Search related documents:
Co phrase search for related documents- abdominal pain and acute respiratory failure: 1, 2, 3, 4, 5, 6
- abdominal pain and loading dose: 1, 2
- abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
- abdominal pain and lopinavir ritonavir favipiravir: 1, 2
- abdominal pain and low degree: 1
- abdominal pain and lung imaging: 1, 2, 3, 4, 5, 6
- abdominal pain and lung imaging finding: 1
- abdominal pain and lupus erythematosus: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date